RedFlag Index™ · #9 of 10 · NASDAQ: AMGN

Amgen Inc.: enforcement record and regulatory exposure

Amgen Inc. scores 42 out of 100 on the RedFlag Index™ (November 2026), ranking #9 of ten tracked companies, with 3 documented cases of which 2 remain open.

2019: Amgen paid $24.75 million over allegations that its copay-charity donations were kickbacks for Sensipar and Kyprolis.

2015: Amgen paid $71 million to 48 states and D.C. over off-label marketing of Enbrel and Aranesp.

2012: Amgen paid $762 million and pleaded guilty to misbranding Aranesp, including a $136 million criminal fine.

DateMatterAmountStatus
December 2023FTC Horizon acquisition consent order with monitorNo penaltyResolved, order in force
April 25, 2019Copay-charity kickback FCA settlement$24.8mResolved
August 201548-state Enbrel and Aranesp off-label marketing settlement$71mResolved
December 2012Aranesp guilty plea and resolution incl. $136m criminal fine$762mResolved

Government enforcement only. Greyed rows are more than ten years old and excluded from scoring under the temporal decay rule.

  1. False Claims Act

    Amgen pleaded guilty over Aranesp and paid $762 million. Then it kept paying.

    The 2012 plea is a criminal conviction. Further settlements followed within months and continued for years.

  2. Merger Conditions

    Amgen remains bound by FTC bundling ban from Horizon Therapeutics acquisition

    The FTC finalised a consent order resolving its challenge, joined by six states, to Amgen's $27.8 billion acquisition of Horizon Therapeutics. The order bars Amgen from bundling its products with Horizon's Tepezza and Krystexxa, requires prior approval for related acquisitions and imposes 15-year compliance obligations under a monitor.